Advanced search
Publication Cover
International Journal of Neuroscience Volume 126, 2016 - Issue 1
Submit an article Journal homepage
317
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease

Clare W. MakumiUS Medical Affairs –Medical Services, GlaxoSmithKline, Research Triangle Park, North Carolina, USACorrespondence[email protected]
,
Afsaneh AsgharianClinical Statistics, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
,
Jeffrey EllisR&D Projects, Clinical Platforms, & Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
,
Soraya ShaikhClassic and Established Medicines, GlaxoSmithKline, Brentford, UK
,
Teri JimenezClinical Statistics, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
&
Susan VanMeterNeuroscience Therapy Area Unit, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
Pages 30-38 | Received 21 Aug 2014, Accepted 22 Nov 2014, Published online: 27 Dec 2014

References

  • Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783–93.
  • Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309–16.
  • Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393–9.
  • Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310.
  • Stocchi F, Hersh, BP, Scott, BL, et al. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008;24(10):2883–95.
  • Pahwa R, Stacy MA, Factor SA et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108–15.
  • Hauser RA, Reichmann H, Lew M, et al. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. Int J Neurosci 2011;121(5):246–53.
  • Tompson, D Vearer D.). Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007;29:2654–66.
  • Stocchi F, Giorgo L, Hunter B, Schapira A. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Movement Disord. 2011;26(7);1259–65.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.